|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The national instistutes of health chronic prostatitis symptom index: development and vaildation of a new outcome measure 显示文摘 | Litwin MS Mcnaughton - collins M Fowler F Jr | 1999 | J Urol1999，162，2： | 1 |
| 2 | Heme oxygenase synthesis is induced in cultured lens epithelium by hyperbaric oxygen or puromycin显示文摘 | Padgaonkar VA Giblin F J Fowler K Leverenz VR Reddan JR Dziedzic DC | 1997 | Exp Eye Res1997，65，3： | 1 |
| 3 | The National Institutes of Health chronic prostatitis symptom index:developmcnt and validation of a ncw outcomc mcasurc显示文摘 | Litwin M S McNaughton-Collins M Fowler F J Jr | | 0，，2： | 1 |
| 4 | The national instistutes of health chronic prostatitis symptom index: development and waildation of a new outcome measure显示文摘 | Litwin MS Mcnaughton-collins M Fowler F Jr | 1999 | J Urol1999，162，2： | 1 |
| 5 | Effect of radical prostatectomy for prostate cancer on patient quality of life:results from a medicare survey显示文摘 | Fowler F J Jr Barry M J Lu Yao G | 1995 | Urology1995，45，6： | 1 |
| 6 | The Na-tional Institutes of Health chronic prostatitis symptom index:de-velopment and validation of a new outcome measure显示文摘 | Litwin M S McNaughton-Collins M Fowler F J Jr | 1999 | J Urol1999，162，2： | 1 |
| 7 | The National Institutes of Health chronic prostatitis symptom index:development and validation of a new outcome measure显示文摘 | Litwin M S McNaughton-Collins M Fowler JR F J | | 0，，02： | 1 |
| 8 | Thermal protection system weight minimization for the space shuttle through trajectory optimization显示文摘 | Garcia F Jr Fowler W T | 1974 | Journal of Spacecraft and Tockets1974，11，1： | 1 |
| 9 | The National Institutes of Health chronic prostatitis symptom index:development and validation of a new out- come measure显示文摘 | LITWIN M S MCNAUGHTON-COLLINS M FOWLER F J JR | 1999 | J Urol1999，162，2： | 1 |
| 10 | The Na-tional Institutes of Health chronic prostatitis symptom index:de-velopment and validation of a new outcome measure显示文摘 | McNaughton-Collins M Fowler F J Jr | 1999 | J Urol1999，162，2： | 1 |
| 11 | The National Institutes of Health chronic prostatitis symptom index:development and validat ion of a new outcome measure显示文摘 | McNaughton-Collins M Fowler F J Jr | 1999 | J Urol1999，162，2： | 1 |
| 12 | ACC/AHA guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure) 显示文摘 | Williams J F Jr Bristow M R Fowler M B | 1995 | J Am Coil Cardiol1995，26，5： | 1 |
| 13 | Effect of radical prostatectomy for prostate cancer on patient quality of life: results from a Medicare survey显示文摘 | Fowler F J Jr Barry M J Lu-Yao G | 1995 | Urology1995，45，： | 1 |
| 14 | The National Institutes of Health chronic prostatitis symptom index: development and validation of new out- come measure显示文摘 | Litwin M S McNaughton-Collins M Fowler F J Jr | 1999 | J Urol1999，162，2： | 1 |
| 15 | The interstitial cystitis symptom index and problem index显示文摘 | O'Leary MP Sant GR Fowler F J Jr | 1997 | Urology1997，49，5： | 1 |
| 16 | The NIH chronic prostatitis symptom index (NIH- CPSl): Development and validation of a new outcomes measure显示文摘 | Litwin MS Mcnaughton-collins M Fowler F Jr | 1999 | 3Urol1999，163，： | 1 |
| 17 | The National Institutes of Health Chronic Prostatitis Symptom Index(NIH-CPSI) : Development and Validation of a New Outcome Measure显示文摘 | Litwin M S MacNaughton Collins M Fowler F J Jr | 1999 | J Uro11999，162，2： | 1 |
| 18 | The national inatistutes of health chronic prestatitis symptom index:development and vaildation of a new outcome measure显示文摘 | Litwin MS Menaughton-collins M Fowler F Jr | 1999 | J Urol1999，162，2： | 1 |
| 19 | The national instistutes of health chronic prostatitis symptom index: develop- ment and vaildation of a new outcome measure 显示文摘 | Litwin MS Mcnaughton - collins M Fowler F Jr | 1999 | J Urol1999，162，2： | 1 |
| 20 | Impact of high dose vitamin C on platelet function显示文摘AIM To examine the effect of high doses of vitamin C(VitC) on ex vivo human platelets(PLTs).METHODS Platelet concentrates collected for therapeutic or prophylactic transfusions were exposed to:(1) normal saline(control);(2) 0.3 mmol/L VitC(Lo VitC); or(3) 3 mmol/L VitC(Hi VitC, final concentrations) and stored appropriately. The Vit C additive was preservative-free buffered ascorbic acid in water, pH 5.5 to 7.0, adjusted with sodium bicarbonate and sodium hydroxide. The doses of Vit C used here correspond to plasma Vit C levels reported in recently completed clinical trials. Prior to supplementation, a baseline sample was collected for analysis. PLTs were sampled again on days 2, 5 and 8 and assayed for changes in PLT function by: Thromboelastography(TEG), for changes in viscoelastic properties; aggregometry, for PLT aggregation and adenosine triphosphate(ATP) secretion in response to collagen or adenosine diphosphate(ADP); and flow cytometry, for changes in expression of CD-31, CD41 a, CD62 p and CD63. In addition, PLT intracellular Vit C content was measured using a fluorimetric assay for ascorbic acid and PLT poor plasma was used for plasma coagulation tests [prothrombin time(PT), partial thrombplastin time(PTT), functional fibrinogen] and Lipidomics analysis(UPLC ESI-MS/MS).RESULTS VitC supplementation significantly increased PLTs intracellular ascorbic acid levels from 1.2 mmol/L at baseline to 3.2 mmol/L(Lo VitC) and 15.7 mmol/L(Hi VitC, P < 0.05). VitC supplementation did not significantly change PT and PTT values, or functional fibrinogen levels over the 8 d exposure period(P > 0.05). PLT function assayed by TEG, aggregometry and flow cytometry was not significantly altered by Lo or Hi VitC for up to 5 d. However, PLTs exposed to 3 mmol/L VitC for 8 d demonstrated significantly increased R and K times by TEG and a decrease in the α-angle(P < 0.05). There was also a fall of 20 mm in maximum amplitude associated with the Hi VitC compared to both baseline and day 8 saline controls. Platelet aggregation studies, showed uniform declines in collagen and ADP-induced platelet aggregations over the 8-d study period in all three groups(P > 0.05). Collagen and ADP-induced ATP secretion was also not different between the three groups(P > 0.05). Finally, VitC at the higher dose(3 mmol/L) also induced the release of several eicosanoids including thromboxane B2 and prostaglandin E2, as well as products of arachidonic acid metabolism via the lipoxygenases pathway such as 11-/12-/15-hydroxyicosatetraenoic acid(P < 0.05).CONCLUSION Alterations in PLT function by exposure to 3 mmol/L VitC for 8 d suggest that caution should be exerted with prolonged use of intravenous high dose VitC. | Bassem M Mohammed Kimberly W Sanford Bernard J Fisher Erika J Martin Daniel Contaifer Jr Urszula Osinska Warncke Dayanjan S Wijesinghe Charles E Chalfant Donald F Brophy Alpha A Fowler Ⅲ Ramesh Natarajan | 2017 | World Journal of Critical Care Medicine2017，6，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员